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Abstract
Predictive, preventive and personalized medicine (PPPM) may have the potential to eventually improve the nature of
health care delivery. However, the tools required for a practical and comprehensive form of PPPM that is capable of
handling the vast amounts of medical information that is currently available are currently lacking. This article reviews a
rationale and method for combining and integrating diagnostic and therapeutic management with information
technology (IT), in a manner that supports patients through their continuum of care. It is imperative that any program
devised to explore and develop personalized health care delivery must be firmly rooted in clinically confirmed and
accepted principles and technologies. Therefore, a use case, relating to hepatocellular carcinoma (HCC), was developed.
The approach to the management of medical information we have taken is based on model theory and seeks to
implement a form of model-guided therapy (MGT) that can be used as a decision support system in the treatment of
patients with HCC. The IT structures to be utilized in MGT include a therapy imaging and model management system
(TIMMS) and a digital patient model (DPM). The system that we propose will utilize patient modeling techniques to
generate valid DPMs (which factor in age, physiologic condition, disease and co-morbidities, genetics, biomarkers and
responses to previous treatments). We may, then, be able to develop a statistically valid methodology, on an individual
basis, to predict certain diseases or conditions, to predict certain treatment outcomes, to prevent certain diseases or
complications and to develop treatment regimens that are personalized for that particular patient. An IT system for
predictive, preventive and personalized medicine (ITS-PM) for HCC is presented to provide a comprehensive system to
provide unified access to general medical and patient-specific information for medical researchers and health care
providers from different disciplines including hepatologists, gastroenterologists, medical and surgical oncologists, liver
transplant teams, interventional radiologists and radiation oncologists. The article concludes with a review providing an
outlook and recommendations for the application of MGT to enhance the medical management of HCC through
PPPM.
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Predictive, preventive and personalized medicine (PPPM)
may have the potential to eventually improve the nature of
health care delivery. This article was initially conceived, and
has gradually evolved, to seek solutions to issues and tasks
relating to information technology (IT) and predictive, pre-
ventive and personalized medicine (PPPM) as identified in
the White Paper 2012 of the European Association for Pre-
dictive, Preventive and Personalised Medicine (EPMA) [1].
Specifically, this article reviews work being done to define
the requirements and interrelationships between PPPM,
clinical medical practice and basic medical research that
could be best served by information technology (IT) [2,3].
To avoid the problems inherent in formulating IT solutions
in isolation, a use case was developed employing hepatocel-
lular carcinoma (HCC). It may be useful to define how the
term use case is employed here. The term ‘use case’ has
been used in software and systems engineering to describe
a system's behavior and appearance and to diagram the
main flow of events in a system as it responds to stimulus
[4,5]. A use case can be used both to define conceptual re-
quirements of a system and to evaluate compliance with
user requirements during testing and evaluation activities
[4]. Software and systems engineering principles relating to
use cases have been extended and applied to medical appli-
cations, for example, to establish a foundation for evaluat-
ing information design in electronic health record (EHR)
applications [4]. In this article, a use case has been adapted
to describe the functional and structural requirements of
an information technology system for predictive, preventive
and personalized Medicine (ITS-PM) by means of generat-
ing a digital patient model (DPM) from available medical
data sources. The use case maintains a focus on the IT as-
pects of the system under development, by limiting the
DPM to entities relating to HCC.
The subject matter of this article was approached from
four separate, but interrelated, tasks: (1) to review
current understanding and clinical practices relating to
HCC; (2) to propose an IT system to deal with the vast
amount of information relating to HCC, including clin-
ical decision support and research needs; (3) to deter-
mine the ways in which a clinical liver cancer centre can
contribute to this IT approach; and (4) to explore the en-
hancements and impact that the first three tasks, and
therefore PPPM, may have on the management of HCC.
One of the goals of this article is to provide an over-
view of a roadmap that is under development for the
generation of IT tools and methodologies to facilitate
PPPM [3]. Our approach to the management of medical
information is based on model theory that has arisen
from a conceptual transformation from image-guided
patient management to more complex model-guided pa-
tient management. This approach seeks to implement a
comprehensive form of model-guided therapy (MGT)
that extends beyond the scope of image guidance and
can be used as a decision support system in the treat-
ment of patients.
It is our hypothesis that if we can utilize patient modeling
techniques to generate valid DPMs (which factor in age,
physiologic condition, disease and co-morbidities, genetics,
biomarkers and responses to previous treatments), we may
be able to develop a statistically valid methodology, on an
individual basis, (1) to predict certain diseases or condi-
tions, (2) to predict certain treatment outcomes, (3) to pre-
vent certain diseases or complications and (4) to develop
treatment regimens that are personalized for that particular
patient. We are calling this proposed system model-based
medical evidence (MBME) and are engaged in its develop-
ment. It is further postulated that the multi-entity Bayesian
networks (MEBNs) used in the construction of the DPM
will be utilized in the development of a practical decision
support system.
The information presented in this review will be used to
identify the patient attributes, or information entities
(IEs), that will be used to populate the patient databases
and MEBNs required for generating DPMs to facilitate
data mining and decision support. For any given patient
with HCC, the DPM will need to be continuously updated
to ensure appropriate guidance of the patient throughout
the course of their disease. The development of an ITS-
PM for HCC will provide a comprehensive system to
identify and then determine the relative value of the wide
number of IEs. This system will be designed to provide
unified access to general medical and patient-specific in-
formation for medical researchers and health care pro-
viders from different disciplines including hepatologists,
gastroenterologists, medical and surgical oncologists, liver
transplant teams, interventional radiologists and radiation
oncologists.
The ‘Review’ section of this article is divided into four
sections:
1. Review of MGT and the proposed IT framework
2. Review of HCC and its current management
3. Identification of IEs relating to HCC
4. Outlook and expert recommendations for PPPM
and HCC
For a more in-depth presentation of the topics discussed
in this review article, the reader is referred to reference [3].
Review of model-guided therapy and the proposed
information technology framework
In the approach to MGT taken here, there are three
basic structures that will be described. The first is the
DPM, which may be regarded as the basic model for
representing a patient. The second structure is a therapy
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imaging and model management system (TIMMS),
which provides the hardware and software components
for MGT. The third structure to be reviewed is the
MEBN, which provides a statistically valid framework
for handling medical information.
The digital patient model
The DPM provides an IT tool needed for collecting,
combining, statistically analyzing, validating and processing
patient attributes and biomarkers into a comprehensive,
understandable, dynamic, real-time view of the patient.
Creation and maintenance of a DPM for any given patient
is built upon a generic patient-specific model (PSM) which
is modified by the addition of actual patient-specific data,
thereby providing a multiscalar, precise, personalized repre-
sentation of the patient [6,7].
A general template for a range of attributes included in a
generic PSM is presented in Figure 1. The central area of
the template represents the current status of the PSM and
is divided into three categories: predetermined factors, ana-
tomic factors and physiologic/functional factors. Allow-
ances are made for those influences that have a direct role
in altering the PSM—processes, such as ageing, growth and
development, diseases and surgical procedures; extrinsic in-
puts or interventions; and intrinsic mediators. A separate
section of the template displays the PSM output that gener-
ates the current or working model of the actual patient or
the DPM.
Features of the patient that are amenable to graphical
representation are maintained as references within the
DPM database structure to picture archiving and com-
munications systems (PACSs) and repositories that allow
access to the actual images. This is achieved through
Figure 1 A generic PSM template. The DPM is generated when the specific factors and values are entered into the full set of templates (one
for each organ system) and the output is analyzed and may be used for prediction.
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functionalities of a suitable IT infrastructure for simulations
and interventions (i.e. TIMMS, see below). This allows
medical images to be loaded into advanced medical work-
stations for purposes of treatment planning and simulation,
as well as allowing real-time interaction with hardware and
software for image-guided interventions, such as radiation
therapy and minimally invasive therapies.
Those features of the DPM that are measurable and/or
have cause-and-effect relationships, and can be quantified,
may be dealt with in a different manner than nonquantifi-
able features, such as constitution and appearance. In
Bayesian terms, these quantifiable features, or information
entities (IEs), may be thought of as a dynamic set of data el-
ements, i.e. attributes with interconnected and fluctuating
probability distributions. These features will be stored in
databases and repositories and will provide the substrate
for the MEBN (see below).
Therapy imaging and model management system
A therapy imaging and model management system
(TIMMS) and its application as a surgical assist system for
achieving MGT have been described [6,7]. A TIMMS is a
comprehensive medical-surgical communication and assist
system (Figure 2) that is composed of interconnected com-
puter hardware and software components (such as engines,
agents, repositories and IT infrastructure) and provides a
wide variety of features and functions throughout the
course of medical and surgical treatment. A TIMMS serves
as a real-time knowledge management and decision sup-
port system, with central functions regulated by the Kernel
for workflow and knowledge and decision management,
promoting optimized diagnostic, prognostic and thera-
peutic decisions throughout the treatment workflow.
The Kernel (or ‘brain’ of the system) provides the stra-
tegic intelligence for therapeutic planning and workflow
execution. The Kernel may use different forms of logic,
different database structuring, agents, machine learning
and other forms of artificial intelligence, depending on
the specific medical application being performed. Agents
may be defined as software modules, containing some
form of intelligence, which, with some degree of auton-
omy and adaptability, carry out functions or tasks.
In addition to the Kernel, there are six TIMMS engines
that may be defined as software modules that can be exe-
cuted on an appropriate computing machine to provide
functionalities. These engines relate to imaging and bio-
sensor data acquisition, modeling, simulation, workflow
and knowledge and decision management, visualization,
intervention and validation.
The DPM is maintained by agents regulated by the
Kernel in conjunction with the modeling engine and
tools, based on data stored in the repositories and/or
available from electronic medical records and other
sources.
Figure 2 The structure of the therapy imaging and model management system (TIMMS). The TIMMS may provide much of the IT framework for
personalized medicine. The Kernel for workflow and knowledge and decision management, the patient-specific models repository and the process models
repository are the central components for the development of digital patient models through the process of patient-specific modeling. ICT information
and communication technology; WF workflow; K+D knowledge and decision; Rep representation; Mechatr mechatronic.
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Multi-entity Bayesian network
Acceptance, understanding and factoring of the uncer-
tain nature of medical knowledge is a key feature of
MGT. The probability distribution of each attribute or
variable of the DPM reflects and represents the state of
uncertainty associated with the knowledge about a par-
ticular feature of an individual patient. The existence of
relationships among attributes, represented by appropri-
ate links and their binding strength, are also subject to
probability distributions. The value of each attribute
probability distribution lies within a statistically defin-
able range of normal and abnormal values. The bound-
aries of the values for each attribute, and the volatility of
the changes of these values, vary in health and disease,
and at different ages, and may be subject to further alter-
ations based on the body's homeostatic mechanisms, as
well as constitutional, genetic and epigenetic, and envir-
onmental factors, including prior medical and surgical
interventions. It is therefore reasonable to assume that
the described situation surrounding the patient is amen-
able to be represented by a form of Bayesian network.
However, standard Bayesian networks that have been
utilized in previous medical decision support and know-
ledge management systems are inadequate for this pur-
pose. A multi-entity Bayesian network (MEBN) [8] has
been developed that can overcome the limitations of
standard Bayesian networks.
A MEBN is a logic system that integrates first-order
logic with Bayesian probability theory and can provide a
descriptive and functional framework for the quantifiable
components or IEs of the DPM. These IEs will be stored
as attributes within both a PSM database and the appro-
priate nodes of the graph created for the MEBN. With the
addition of sufficient context-appropriate patient-specific
data, it is hypothesized that the MEBN will provide a flex-
ible and sufficiently accurate model of a patient and will
also provide the necessary framework for the associated
situational awareness and decision support that will be re-
quired for the performance of MGT.
An IT system for predictive, preventive and personalized
medicine for HCC
The development of an IT system for predictive, preventive
and personalized medicine (ITS-PM) for HCC will provide
a comprehensive system to identify and then determine the
relative value of the wide number of variables or IEs: (1)
factors reflecting clinical assessment of the patient includ-
ing functional status, liver function, degree of cirrhosis and
co-morbidities; (2) factors reflecting tumor biology, at a
molecular, genetic and anatomic level; (3) factors reflecting
tumor burden and individual patient response; and (4) fac-
tors reflecting medical and operative treatments and their
outcomes.
The ITS-PM for HCC will provide unified access to gen-
eral medical and patient-specific information for medical
researchers and health care providers from different disci-
plines including hepatologists, gastroenterologists, medical
and surgical oncologists, liver transplant teams, interven-
tional radiologists, and radiation oncologists.
In order for the ITS-PM to handle vast amount of in-
formation, we will need to define and develop new types
of database solutions and end-user applications. The
database solutions should include certain features—eas-
ily accessible links to data sources and repositories, func-
tionality that is well organized and easily expandable, the
facility for queries that will promote probabilistic and
statistically valid investigations and features to facilitate
decision support and research.
Beyond the selection and development of database sys-
tems, the larger task is to find a way of using IT to pool,
integrate and correlate the following: (1) the clinical in-
formation relating to diagnosis and treatment of HCC;
(2) the research data relating to epidemiology, virology
and pathology at the anatomic, molecular and genetic
levels; and (3) the role of MGT and patient-specific
modeling.
One of our goals is to propose a realistic, plausible ap-
proach to the development of DPMs, based on a complex
of database and knowledge management systems capable
of data storage, data mining, data analysis and decision
support. It is imperative that comprehensive and cohesive
hardware and software architecture is provided for the
ITS-PM to allow each section to function independently,
while synchronized and in communication with each
other section. At this time, there is no system or collection
of systems on the market that can accomplish these tasks.
However, Reference Model for Open Distributed Process-
ing (RM-ODP) and service-oriented architecture (SOA)
(which may be considered a subset of RM-ODP and is
perhaps more widely known) are standards, methodolo-
gies or approaches to enterprise system development that
could help fulfill the necessary requirements [9,10].
It is beyond the scope of this article to provide a
complete RM-ODP enterprise proposal with detailed
SOA schema. However, at this stage of development, a
simplified schematic for the organization of an ITS-PM
is presented in Figure 3 for illustrative purposes.
Review of HCC and its current management
In this section, the clinical information required for con-
structing a preliminary MEBN for HCC will be reviewed
and presented. Appropriate IEs will be extracted from
the data presented here, so that in future works, a
MEBN and a generic PSM template for HCC can be
developed.
Once the preliminary MEBN and PSM template have
been established, the addition of patient records, images
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and outcomes stored in the appropriate TIMMS repositor-
ies will allow the creation of a functioning MEBN. It is our
goal to utilize this IT approach to medical management to
maximize the use of established medical information, to as-
sist decision making, to advance our understanding of
health and disease, especially when there is incomplete
medical knowledge, and to facilitate PPPM.
Hepatocellular carcinoma
HCC is the most common form of primary liver cancer,
the fifth most common cancer worldwide and the second
leading cause of cancer death in the world [11]. Due to its
aggressive nature and poor survival rate, incidence and
mortality rates are almost equivalent, accounting for ap-
proximately 500,000 deaths annually. Since HCC is most
often seen in patients with chronic liver disease or cirrho-
sis, the incidence of HCC and the epidemiology of under-
lying liver diseases are closely linked.
The development of HCC is currently felt to take place in
a sequential process, with transformation from a small
monoclonal dysplastic focus (<1 mm) to a low-grade dys-
plastic nodule (LGDN) (>1 mm) and then to a high-grade
dysplastic nodule (HGDN) before it evolves into a true car-
cinoma [12]. One of the distinguishing features of early
HCC is stromal invasion into the portal tracts. In addition,
early diagnosis of HCC is supported by molecular markers
(glypican 3, heat shock protein 70 (Hsp70) and glutamine
synthetase). If two of these three markers are positive, a
sensitivity of 72% and specificity of 100% are reached for
the diagnosis of HCC [12]. Transformation into carcinoma
is further accompanied by the recruitment of an arterial
blood supply, venous invasion and, finally, metastasis. Some
of these features will be exploited in the early detection of
HCC by contrast-enhanced computed tomography (CT)
and magnetic resonance imaging (MRI).
There is evidence that oxidative stress and chronic in-
flammation form common carcinogenic risk factors in all
primary liver cancers. Chronic viral hepatitis B and C, alco-
holic and non-alcoholic steatohepatitis, metabolic diseases
and mutagens, such as aflatoxins, are the most important
risk factors for the development of HCC. A number of
genetic markers have been associated with poor prognosis
in HCC (more rapid progression, earlier recurrence after
surgical resection or transplant) and include primarily
keratin 19 (K19), keratin 7 (K7), EpCAM, AE1-AE3, alpha-
fetoprotein (AFP), MRP1 and vimentin. In addition, high
expression of adenosine triphosphate-binding cassette
(ABC) transporters, such as MDR1, ABCG2 and ABCC2,
renders the cells resistant to chemotherapy, including cis-
platin and doxorubicin, which can be reversed with inhibi-
tors or by using an antisense approach [12].
The relationship between HCC and infection with
hepatitis B virus (HBV) and hepatitis C virus (HCV) and
with cirrhosis is of paramount importance. Up to 80% of
HCC is attributable to HBV or HCV worldwide [13,14].
The risk of HCC is increased 5- to 15-fold in chronic
HBV carriers [15,16] and 11.5- to 17-fold in HCV-
infected patients [16,17]. Antiviral therapy is effective in
preventing HCC in only a small proportion of patients
[18,19], and sustained clearance of HBV or HCV may be
difficult to accomplish, particularly among cirrhotic pa-
tients. Of all HCCs, 80–90% develops in a cirrhotic liver
[20]. After 20–30 years of chronic infection, 20–30% of
patients develop liver cirrhosis. HCC develops at an an-
nual rate of 1–7% in HCV-infected cirrhotic patients
[14] and 3–8% in HBV-infected cirrhotic patients [21].
Figure 3 A schematic for organization of an ITS-PM. This diagram reorganizes many of the TIMMS components in a structure that will enable
the secure interchange of information between data sources, database management systems, data analysis systems and end-user applications.
(PSM patient-specific model; TIMMS therapy and imaging model management system; PACS picture archiving and communications system; MEBN
multi-entity Bayesian network; NoSQL not only structured query language; DBs databases.
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Screening for HCC in high-risk individuals is recom-
mended since early identification of small tumors has
been reported to lead to improved survival [22,23].
High-risk individuals include hepatitis B carriers and
those with cirrhosis caused by HCV, alcoholic liver dis-
ease, genetic hemochromatosis, primary biliary cirrhosis
and autoimmune hepatitis [24]. Ultrasound (US) has
been recommended as a non-invasive imaging modality
for screening for HCC, with a >60% sensitivity and
>90% specificity in detecting HCC [25]. US has been
recommended as a non-invasive imaging modality for
screening for HCC, with a >60% sensitivity and >90%
specificity in detecting HCC [25].
AFP is a serologic marker that is elevated in many pa-
tients with HCC and is usually diagnostic in patients
with serum levels >500 mcg/L [26]. However, due to its
limited sensitivity and specificity, AFP should not be
used alone as either a screening agent or diagnostic tool
[27]; however, AFP may be helpful in making a diagnosis
of HCC in conjunction with imaging modalities.
There are a number of systems available for staging
and classifying HCC. We will focus on the Barcelona
Clinic Liver Cancer (BCLC) staging system and its up-
dates [28-31] (Figure 4). The BCLC staging system is
based on performance status, extent of tumor including
presence or absence of vascular invasion, bilirubin level,
presence or absence of portal hypertension and Okuda
stage. This system is advantageous in that it classifies pa-
tients as very early, early, intermediate, advanced or ter-
minal stages thereby establishing a link between stage of
disease and appropriate treatment modalities. Very early
stage disease is difficult to diagnose since patients are
Child-Pugh class A, have no clinical features of liver dis-
ease and have a single HCC lesion <2 cm. If diagnosis is
made at this stage, the treatment of the tumor has a the-
oretical 5-year survival rate of 100% [28-31]. Early-stage
disease includes patients with up to three nodules, each
less than 3 cm, and well-preserved liver function (Child-
Pugh class A and B).
Appropriate treatment for early-stage disease includes
resection, liver transplantation or ablation with a 5-year
survival rate approaching 75% [28-31]. Those with inter-
mediate disease are Child-Pugh class A or B and have
large (>5 cm) or multifocal disease without vascular in-
vasion or intrahepatic spread. Transarterial chemoembo-
lization (TACE) is most appropriate for these patients as
a means to prolong survival, but not necessarily as a
long-term cure [28-31]. Advanced-stage disease includes
Figure 4 The Barcelona Clinic Liver Cancer (BCLC) staging system for hepatocellular carcinoma, revised 2011. PST performance status;
CLT/LDLT cadaver liver transplant/living donor liver transplant; RF/PEI radiofrequency ablation/percutaneous ethanol injection; TACE transarterial
chemoembolization [29].
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patients who have cancer-related symptoms, vascular in-
vasion or extrahepatic spread of tumor. Although cure is
not a realistic goal in most of these patients, treatment
with TACE [32] or sorafenib [33], an oral multikinase
inhibitor, may prolong life. Finally, patients who have
extensive disease (extensive tumor involvement, Child-
Pugh class C) are classified as having terminal stage dis-
ease and have a <10% 1-year survival [32]. Treatment
goals for these patients should be geared towards palli-
ation and management of symptoms.
Radiologic assessment of hepatocellular carcinoma
In the setting of a multidisciplinary clinical liver cancer
centre, radiologists play an essential role in the different
phases of HCC patients' management, including diagno-
sis, staging, treatment planning and evaluation of re-
sponse to treatment.
According to the BCLC staging system, treatment deci-
sions and prognosis are strongly influenced by the tumor
extension, in terms of lesions' number and size, presence
of macrovascular invasion and extrahepatic tumor spread;
precise tumor identification is therefore mandatory for
proper patient allocation [28]. Moreover, treatment is
often determined by other parameters that are not specif-
ically addressed in the BCLC algorithm, such as tumor
location, biliary dilatation, ascites, co-morbidities and
radiological response to previous treatments. Therefore, in
clinical practice, clinical data need to be fully integrated to
an entire spectrum of radiological parameters.
The development of a neoplasm in cirrhosis is a long-
lasting process. Many cellular changes occur along the
pathway from normal hepatocytes to neoplastic cells so
that different types of nodules can be detected in a
cirrhotic liver, ranging from regenerative nodules to low-
grade dysplastic nodules (LGDNs) and high-grade
dysplastic nodules (HGDNs), early HCC and, finally,
overt HCC.
HGDNs and early HCC are considered as premalig-
nant and early malignant nodules. Foci of HCC can be
found inside HGDNs, while in early HCC, cell degener-
ation is usually not already associated with the typical
vascular changes found in overt HCC [34,35]. These vas-
cular alterations include the reduction of portal venous
supply and the development of unpaired arteries and ar-
teriovenous shunts [35]. These typical vascular changes
account for the pathological background for current
non-invasive diagnosis of HCC at dynamic contrast-
enhanced imaging, based on the so-called typical vascu-
lar pattern, characterized by wash-in in the arterial phase
and wash-out in the portal venous/late phases. This pat-
tern has shown up to 100% specificity for HCC nodules
>1 cm in size, in the setting of a cirrhotic liver [36-38].
Only two thirds of HCCs are reported to show a typ-
ical vascular pattern, and diagnosis of atypical HCC
nodules remains a controversial issue, with differences in
their suggested management according to the available
guidelines [39]. While both European Association for
the Study of the Liver (EASL) and American Association
for the Study of Liver Diseases (AASLD) guidelines sug-
gest biopsy for all atypical nodules >1 cm [29-31], the
EASL guidelines suggest the use of new diagnostic tools,
such as magnetic resonance (MR) using reticuloendothe-
lial system (RES) or hepatocyte-specific contrast agents
or contrast-enhanced ultrasound (CEUS) using Sonazoid
[40], while biopsy should be performed in case of incon-
clusive findings.
New diagnostic tools
Despite being very specific, the diagnosis of HCC based
solely on the detection of neoangiogenesis has a low sensi-
tivity. Thus, the role of different diagnostic elements is
under evaluation [36]. In this setting, MR seems to pro-
vide some advantages compared to multidetector com-
puted tomography (MDCT), due to its intrinsic capability
of identifying other intracellular components, such as
glycogen, hemorrhage, water and metals, and defining
other parameters, such as diffusivity and biliary function
[41-43].
Diffusion-weighted imaging Diffusion-weighted im-
aging (DWI) is a dedicated MR sequence that allows for
the evaluation of the random motion (related to thermal
effects) of water molecules (‘Brownian motion’) within
biological tissues. Recently, DWI has been introduced in
liver MR protocols, as several studies have reported its
usefulness in improving detection and characterization of
focal liver lesions, by measuring their apparent diffusion
coefficient [44,45], providing an adjunctive tool in the dif-
ferential diagnosis between benign and malignant lesions.
Hepatospecific contrast agents for MR During carcino-
genesis, together with neoangiogenesis, progressive loss of
biliary polarization of the hepatocyte and derangement of
its microscopic, secretory structure are observed. Recent
studies have described modifications of membrane carriers
(such as organic anionic transporter protein [OATP] and
multidrug-resistance protein [MRP]) that are involved in
bilirubin metabolism in neoplastic nodules.
The recent introduction of hepatobiliary contrast agents
in MR studies, especially of the highly lipophilic com-
pound Gd-EOB-DTPA, has provided an additional tool
for the assessment of the metabolic function of nodules.
In fact, due to a competitive binding to bilirubin trans-
porters, these agents provide information regarding the
residual performance of cellular membrane proteins and
intracellular metabolic activities [46,47].
Moreover, these agents enable the evaluation of both
dynamic vascular and metabolic nodular functions in a
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single-session study since the contrast is taken up within
functioning hepatocytes and then excreted at the level of
the biliary pole at the end of the intravascular phase.
This metabolic phase occurs 20 to 40 min after the
injection.
In recent studies, the lack of contrast agent uptake in the
hepatobiliary phase has been found in premalignant
HGDNs, as well as cases of malignant degeneration (early/
overt HCC), even in the absence of the typical vascular pat-
tern [8,36,37,48]. Thus, the use of hepatobiliary contrast
agents might increase MR sensitivity in identifying malig-
nant and premalignant lesions. Accordingly, recent studies
have demonstrated that the combination of DWI and MR
with hepatospecific contrast agents can provide information
regarding the risk of premalignant lesions evolving into
overt HCC [42,43].
Radiological findings that may be used to generate IEs
are summarized in Table 1.
Role of positron emission tomography
In the last two decades, the development of positron emis-
sion tomography (PET) and then PET with computed tom-
ography (PET/CT) imaging has had a large impact on the
management of a number of cancer types. PET/CT imaging
benefits from the possibility to obtain both structural (CT)
and functional (PET) cancer information at the same time.
PET obtains images of the biodistribution of radioactive la-
beled compounds (radiopharmaceuticals) that can be de-
signed to target different biological processes.
Several radiopharmaceuticals are available for PET for
imaging various aspects of cancer biology such as cell
proliferation and DNA synthesis, tumor hypoxia, tumor
angiogenesis and cell apoptosis. However, in current
clinical cancer imaging, most PET imaging studies are
performed using an analogue of glucose, fluorodeoxyglu-
cose (FDG), labelled with the radioactive Fluorine-18 [18
F]. Imaging with FDG is particularly useful because fol-
lowing malignant transformation, various tumors are
characterized by increased glucose utilization that is
reflected by increased uptake and accumulation of FDG.
In oncology, PET imaging with FDG often provides more
sensitive and more specific information about the extent of
disease than morphologic/anatomic imaging alone. The
metabolic activity of neoplastic tissue measured by PET
offers information about cancer biology and aggressiveness
and has proven to offer, in comparison to other imaging
modalities and for most cancer types, an improved ability
to differentiate benign from malignant lesions and therefore
to identify early truly neoplastic disease. PET offers also an
earlier and often better assessment of response to treatment
and an overall better accuracy to restage disease after com-
pletion of a treatment course. This in turn results in an
overall improved prognostic evaluation during and after
treatment.
Chemotherapy for HCC
Among the major risk factors for HCC is infection with
HBV or HCV. These particular hepatic pathogens are in-
volved in a multifaceted process that involves a number
of alterations that are genetic and epigenetic, such as the
activation of cellular oncogenes and the inactivation of
tumor suppressor genes.
Systemic therapy with single-agent or combination
chemotherapy has been studied extensively. However,
cytotoxic chemotherapy traditionally has been associated
with low response rates and questionable disease
control. Although systemic chemotherapy has a limited
role in HCC, recent advances in molecular targeted ther-
apies appear to be leading to an increasing role for
chemotherapy.
New data on the efficacy of molecularly targeted
agents have brought these agents, particularly sorafenib,
to the forefront of therapy for advanced HCC. Sorafenib
is a multitargeted, orally active, small molecule tyrosine
kinase inhibitor (TKI) that inhibits Raf kinase and the
VEGFR intracellular kinase pathway [49].
Sorafenib offers the potential for prolonged survival,
although objective tumor remissions are scarce. This
molecular targeted therapy would be the first-line treat-
ment in patients with Child-Pugh B cirrhosis and ad-
vanced HCC who are not candidates to undergo liver
transplant, surgical resection, TACE or radiofrequency
ablation (RFA). Most physicians would not prescribe so-
rafenib for patients with HCC and Child-Pugh C cirrho-
sis, due to the significantly abnormal liver function and
the high risk of treatment-related toxicity.
Systemic chemotherapy is an option for patients whose
tumors progress while on sorafenib and whose performance
Table 1 Radiological features that may be employed as information entities
Clinical task Radiological findings
Preprocedural assessment (a) Number and size of HCC nodules; (b) number and size of nodules considered at risk for neoplastic degeneration; (c)
presence and extension of portal vein neoplastic thrombosis; (d) presence of extrahepatic tumor spread; (e) radiological
signs of cirrhosis (including varices and ascites); (f) biliary dilatations; (g) radiological signs of co-morbidities
Treatment planning (a) Features of nodules such as location, degree of vascularization and presence of pseudocapsule; (b) vascular mapping;
(c) technical details of previous treatments
Evaluation of previous
treatment
(a) Complications; (b) tolerability and compliance; (c) radiological response
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status and liver function are sufficient to tolerate it. The best
regimen is not established. The side effect profile of each in-
dividual regimen must be carefully considered in patients
who have advanced liver disease and/or a short life expect-
ancy. Doxorubicin monotherapy is rarely used in the treat-
ment of HCC. Given the cardiotoxic side effects and low
response rates, the treatment would be considered for pa-
tients who failed molecular targeted therapy and still exhibit
a moderate/fair performance status, with fairly intact liver
and cardiac function. 5FU/leucovorin treatment candidates
would include the elderly, poor performance status patients
and those who are classified as Child-Pugh class C.
Surgical treatment of hepatocellular carcinoma
The treatment of HCC has undergone evolution and re-
finement over the past three decades. Changes in the
understanding of HCC in the context of a wide variety
of factors such as tumor size, number and location,
underlying liver function and portal pressure and hepatic
anatomy, in combination with refinement of surgical
techniques and technologies, have greatly influenced the
approach to surgical management.
Surgery is considered the mainstay of curative HCC
treatment with resection and transplantation achieving
the best outcomes in well-selected candidates (5-year
survival of 60–80%) [29]. In general, surgical resection of
HCC, especially within the Milano/Mazzaferro criteria
for liver transplantation (i.e. solitary tumor ≤5 cm or up
to three tumors all ≤3 cm) in patients with well-
preserved underlying liver function (Child-Pugh A and
selectively B patients), offers the greatest chances for
survival, while liver transplantation, in patients with
compromised liver function (Child-Pugh B/C), is gener-
ally considered the treatment of choice. It is important
to note that these recommendations are undergoing
constant reassessment and revision. The application of
specific techniques, such as RFA and the practice of re-
classification of patients with well-compensated liver
function, have, in some reports, suggested alternative
treatment protocols.
The following areas have been identified as key issues
relating to PPPM and surgical treatment for HCC:
1. Tumor characterization, such as size, number and
vascular invasion
2. The patient's clinical status, particularly the presence
of cirrhosis, the degree of portal hypertension and
liver functional reserve
3. Preoperative management, such as patient selection
for resection or transplantation, choice of donor,
down-staging and bridging therapies
4. Surgical techniques, including techniques to
minimize blood loss during surgery and to ensure an
adequate liver remnant
Ablation therapies for hepatocellular cancer
A wide variety of minimally invasive, or locoregional,
therapies are now available for the treatment of HCC
along with surgery, systemic chemotherapy and, occa-
sionally, radiation therapy. These therapies include ther-
mal ablation, including radiofrequency ablation (RFA),
interstitial laser thermotherapy (ILT), microwave abla-
tion (MWA), high-intensity focused ultrasound (HIFU)
and cryotherapy (CRYO) and nonthermal ablations in-
cluding alcohol injection (ETOH), irreversible electro-
poration (IRE) and photodynamic therapy (PDT).
At this time, RFA has the largest clinical experience
and will serve as the prototype for understanding the
principles, mechanisms and methods that have been de-
veloped for the treatment of HCC. The effectiveness of
RFA, and of more recent forms of ablation therapy, will
be reviewed. Percutaneous, catheter-directed therapy, or
transarterial chemoembolization (TACE), and catheter-
directed radiation therapy with Yttrium-90 will be
reviewed below.
Introduction to tumor ablation Tumor ablation in-
volves a focal destruction of tissue to achieve a therapeutic
effect. The targeted tissue is focal as well, demonstrable
under direct visualization, palpation or via radiologic im-
aging; multiple foci are individually targeted. The thera-
peutic effect may be an attempt at local cure of a tumor
or may be for debulking a tumor for symptomatic (i.e.
pain) reasons. The term ablation suggests immediacy to
the effect, while the results of a tumor ablation may ‘ma-
ture’ post-procedurally; the primary direct effects are usu-
ally most notable.
Ablation can be practiced in various venues: by a sur-
geon in the operating room, in an open procedure or
under laparoscopy or by an interventional radiologist in
a modern hybrid suite or in a simple procedure room.
For our purposes here, we discuss image-guided thermal
ablation. This suggests an interventional setting in which
US, CT, fluoroscopy, MRI or PET could be the imaging
modality of choice. In such a setting, the ablation is per-
formed with a minimally invasive approach—the effect is
delivered interstitially and intratumorally via a device
placed percutaneously. In a percutaneous procedure, im-
aging plays a critical role in the targeting of the lesion,
the protection of the surrounding anatomy and, if pos-
sible, in the monitoring and control of the ablation
process.
Forms of ablation Thermal ablations take advantage of a
number of energy sources including electric current (RFA),
electromagnetic radiation (MWA, LASER) and mechanical
waves (HIFU). Tissue death occurs at 60°C, but in clinical
use, the probes generate over 90°C temperatures. Contem-
porary cryotherapy uses a closed circuit of high-pressure
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gas to draw heat from tissue. Cell death takes place at tem-
peratures below −40°C. These various thermal agents have
each been engineered into various delivery devices. Clinical
systems to treat tumors in all parts of the body include the
liver, kidney, lung, adrenal, bone, soft tissue and more.
The efficacy of RFA is related to the size of the liver
tumor. It is accepted that the lesion should not exceed
2.5–3.0 cm to obtain complete necrosis [49]. It has been
reported that certain microwave ablation (MWA) de-
vices may allow successful treatment of lesions as large
as 5 cm with an acceptable margin of safety [50]. Not-
withstanding, RFA commonly is utilized for lesions
greater than 3 cm in diameter, occasionally for palliative
debulking rather than for cure.
Guidelines may assist in the selection and use of the
more widely used thermal technologies: RFA, MWA and
CRYO. To achieve maximal effectiveness for cure, basic
treatment precepts analogous to those in surgery must
be understood and adhered to, including the following:
(1) proper patient selection, (2) treatment of the entire
lesion and (3) providing adequate tumor margins. For
ablation therapies, certain additional considerations in-
clude (1) avoidance of anatomic structures that influence
effective deposition of energy, such as blood vessels that
divert energy from the tumor (‘heat sink’ or ‘cold sink’);
(2) avoiding tissue alterations that could influence en-
ergy deposition, such as too rapid increase in tissue im-
pedance, tissue charring and creation of microscopic gas
bubbles; (3) ensuring complete coverage when overlap-
ping zones of treatment are required so that no gaps of
inadequately treated tumor cells remain; and (4) ensur-
ing an adequate treatment margin when the tumor is in
proximity to sensitive or vital structures (e.g. GI tract or
myocardium).
Catheter-directed delivery of therapy for hepatocellular
carcinoma
Techniques have been developed for catheter-directed
delivery of therapy for HCC since the 1980s and are
still undergoing evolution. This has included bland
embolization with particles, as well as delivery of che-
motherapeutic agents with a variety of materials, re-
ferred to as TACE.
TACE is made both feasible and effective due to the
dual blood supply of the liver. HCC derives 95% of its
blood supply from the hepatic artery, whereas normal
hepatic parenchyma is supplied 75 and 25% by the portal
vein and hepatic artery, respectively. (These differences
in arterial supply account for the detectability of early
HCC on dynamic, contrast-enhanced CT and MRI.) Ad-
vances in catheter and guide wire technology have been
accompanied by the development of techniques for the
superselective placement of catheters for the safe and ef-
fective delivery of therapeutic agents to hepatic tumors.
Current recommendations based on the Barcelona
Clinic Liver Cancer (BCLC) staging classification and
treatment schedule [29-31] advise TACE for patients
with intermediate stage (Okuda stage 1–2; Childs-Pugh
stage A to B; performance status 0) with multinodular
HCC. Childs-Pugh Class B and C cirrhotic patients, as
well as patients with end-stage HCC, are at an increased
risk for liver failure and death and are not appropriate
candidates for TACE [24].
Combination therapy with RFA and TACE may lead to
more extensive tumor necrosis than mono-ablative ther-
apy and may be a more effective treatment for HCC
[51]. For patients with single nodules between 3 to 5 cm
in size, the combination of RFA and TACE has proven
to be more effective compared to RFA alone [52,53].
The intermediate stage is composed of a very heteroge-
neous population, ranging from patients with a single
large nodule to patients with multifocal extensive bilobar
involvement. In clinical practice, there is wide variation
in the management of these patients. Single large nod-
ules can be treated effectively by surgical resection,
down-staging followed by liver transplant (in highly se-
lected patients) or by combining TACE and RFA [54].
Further study will be needed to determine the effective-
ness of combining RFA and TACE and in which order.
The combination of TACE with antiangiogenic agents,
such as sorafenib, is under investigation as well [55,56].
The use of sorafenib may curtail the post-TACE rise in
VEGF-mediated signaling and simultaneously target
tumor foci distant from the site of treatment.
Radiation therapy for hepatocellular carcinoma
Optimizing the therapeutic ratio and achieving an safety
profile in the treatment of HCC with radiation therapy
(RT) has historically been a challenge. Although HCC is a
radiosensitive tumor, it is surrounded by highly radiosensi-
tive organs, including the remainder of the liver and hol-
low gastrointestinal viscera. As technology has advanced
to the point of allowing a highly conformal dose to be de-
livered to the tumor while sparing the surrounding normal
tissues, radiotherapy has re-emerged as a viable treatment
modality for many patients with HCC, pending random-
ized controlled trials to confirm its efficacy.
Stereotactic body radiotherapy
Stereotactic body radiotherapy (SBRT), which involves the
precise delivery of highly conformal, image-guided, abla-
tive doses of external beam radiation in an abbreviated
course of five fractions or less, has been shown to be an
effective alternative to other ablative procedures in non-
surgical candidates with tumors up to 6 cm in size. To en-
sure that enough residual liver is spared from RT, it is
important to keep the target volume as small as possible,
which has been made feasible through the use of advanced
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treatment-planning technologies like multiphasic and
multimodality imaging, breathing motion management,
highly conformal plans and image-guided treatment deliv-
ery. The safety and efficacy of SBRT has been shown in
several prospective studies of metastatic lesions in noncir-
rhotic livers [57,58], and in the past few years, data has
also emerged from several groups reporting success in
treating HCC with SBRT in patients with cirrhosis.
Child-Pugh class is an important predictor of morbid-
ity for patients undergoing SBRT, and while there is suf-
ficient safety data in class A, SBRT should be used with
caution (or not at all) in classes B and C. The presence
of portal vein thrombosis does not impact the safety or
efficacy of SBRT. Other procedural considerations to
prevent toxicity, which are not contraindications per se,
include keeping an interval of 14 days between SBRT
and chemotherapy and 6 months between SBRT and any
local embolization procedure. There may also be some
situations in which SBRT is technically feasible, but sys-
temic therapy or best supportive care is more appropri-
ate than any local therapy, including patients with life
expectancy <12 weeks, or patients with progressive or
untreated gross extrahepatic disease.
Radioembolization The technique of radioemboliza-
tion is similar in many ways to any other embolization
procedure (e.g. TACE), in that it involves catheter-based
infusion of particles targeted at the branches of the hep-
atic artery that feed the portion of the liver where the
tumor is located. However, the mechanism of action in
radioembolization is primarily due to radiation-induced
necrosis and does not rely on ischemia secondary to
reduced blood flow to achieve tumor necrosis. There
are two different radioisotopes used for radioemboliza-
tion worldwide, iodine-131[I-131]-labeled Lipiodol and
yttrium-90[Y90]-labeled microspheres. Since radioem-
bolization has minimal embolic effect, and will not ob-
struct the blood supply to the functional liver, it is often
considered the safer alternative to TACE for tumors
with portal vein thrombosis.
Prior to treating a patient, it is important to perform a
99m-Tc macroaggregated albumin (MAA) scan to demon-
strate that there is no shunting of blood flow to the lung
or gastrointestinal tract that cannot be corrected by cath-
eter techniques. The potential for ≥30 Gy radiation expos-
ure to the lung is considered an absolute contraindication
to radioembolization. Relative contraindications include a
limited hepatic reserve, irreversibly elevated bilirubin, and
prior RT involving the liver.
According to the Radioembolization Brachytherapy
Oncology Consortium Consensus Guidelines, radioem-
bolization may be used in patients with unresectable pri-
mary HCC with liver-dominant tumor burden and life
expectancy >3 months [59].
Identification of information entities relating to
hepatocellular cancer
In the preceding sections, we have defined the current
state of knowledge, as well as the limits of our knowledge,
with respect to HCC. To advance PPPM, we will be
examining HCC from a more integrated point of view,
combining epidemiology, risk factors, infectious etiologies,
pathology, microenvironment and biomarkers, screening
and diagnostic technologies and treatment modalities (sin-
gle, combined and/or sequential). The IEs identified will
be used in organizing and populating the databases re-
quired for the development of the DPMs and MEBNs for
an ITS-PM, as described above.
First- and second-order IEs for the generic PSM for
HCC are identified in the first two columns in Figure 5.
The attributes of these entities may be obtained through
links with the appropriate databases, spreadsheets, elec-
tronic medical records (EMRs) and repositories, for ex-
ample, by means of the functionalities of a TIMMS.
These first- and second-order IEs are broken down into
third-order IEs and further subdivisions that include the
vast, and continually expanding, list of patient-related
information.
Fourth- and fifth-order IEs for HCC, as identified in
‘Review of HCC and its current management’ section of
this article, are identified in Figure 6. The attributes of
these entities may also be determined through links with
the appropriate databases, spreadsheets, electronic med-
ical records (EMRs) and repositories by means of
TIMMS functionalities.
Figure 7 identifies fourth- and fifth-order IEs for HCC
relating to potential biomarkers and targeted therapies.
It is postulated that a comprehensive DPM incorporat-
ing the combined IEs will provide insights facilitating
and enhancing diagnosis and treatment of HCC, as well
as providing a means of handling research data relating
to epidemiology, virology and pathology at the anatomic,
molecular and genetic levels.
As these IEs are fully identified, the next goal will be
the development of the databases that incorporate these
patient-specific IEs and the development of MEBNs,
DPMs and an ITS-PM. It is important to keep in mind
that a MEBN is a logic system that integrates first-order
logic with Bayesian probability theory [8] and can pro-
vide a descriptive and functional framework for the
DPMs. It is the nature of a MEBN to increase in overall
accuracy, according to Pearl's Bi-directional Belief Up-
dating Algorithm [60,61], as more experience and evi-
dence are added to the system and the precision of the
data used to generate the various component probabil-
ities increases. As the databases are populated with data
from a growing number of patient records, and as more
DPMs are developed, it will then become possible to
begin the study and validation of PPPM through MGT.
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We have called this approach model-based medical evi-
dence (MBME). With the addition of sufficient context-
appropriate patient-specific data, it is hypothesized that
the combined components of the ITS-PM will provide a
flexible and sufficiently accurate model of a patient and
will also provide the necessary framework for the associ-
ated situational awareness and decision support that will
be required for the performance of PPPM. The develop-
ment of MBME will be augmented by the incorporation
of information extracted from RCTs, as well as other
data sources. The ultimate goal of MBME is to promote
an approach to patient care based on a personalized, as
well as global, understanding of diseases and of treat-
ment outcomes, in a way that broadens the scope of
evidence-based medicine. It may be possible to retro-
spectively study large groups of patients who have re-
ceived certain treatments and identify subpopulations of
patients who have responded favorably. If the population
of patients is sufficiently large, evaluation of the DPMs
of these patients may yield constellations of IEs that may
provide prognostic information for future patients.
Outlook and expert recommendations for PPPM and HCC
In this concluding section, the proposed benefits of the
ITS-PM will be presented in the form of outlook and
expert recommendations for PPPM and HCC. It has been
our assumption that the development of a comprehensive
IT system will allow the accumulation and organization of
vast amounts of patient-specific information and will be
designed to perform statistically valid data synthesis and
processing. It is intended that this system helps lead to
more personalized patient evaluation and treatment
choices rather than patient management based primarily
upon local availability and expertise. It is hypothesized
that through the accumulation of sufficiently large num-
bers of DPMs, constellations of IEs will be identified that
provide prognostic information that is patient-specific.
In the short term, more immediate benefits of developing
an ITS-PM for HCC may include enhancements in screen-
ing, use of targeted therapies, combined locoregional ther-
apies and flexible and expanded treatment algorithms.
Extensions to the BCLC staging system algorithm
The BCLC staging system algorithm is an important ad-
vancement in the application of the principles of PPPM in
cancer treatment. The IEs identified in ‘Identification of
information entities relating to hepatocellular cancer’ sec-
tion may be used to expand and reinforce the algorithm in
several ways. Extensions may be added to the algorithm
(Figure 8) that (1) facilitate enhanced screening for HCC,
Figure 5 A portion of a simplified entity-relationship diagram for a relational database is shown displaying the 1st-, 2nd- and 3rd-order
information entities of a generic patient-specific model and a 4th-order entity: hepatocellular carcinoma. INT integer; VARCHAR includes text
[characters, numbers and punctuation].
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Figure 6 A portion of a simplified entity-relationship diagram for a relational database is shown displaying the 5th-order information
entities relating to hepatocellular carcinoma.
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(2) explore ways in which targeted therapies may be used
to improve outcomes and (3) provide statistically validated
evidence regarding the selection of the best treatment
from the many options available for palliative, down-
staging and bridging therapies.
Enhanced screening and shift to the left It may be
possible to positively influence where in the BCLC staging
system a patient enters the algorithm. It would be desir-
able to achieve a shift to the left with a greater number of
patients seeking medical attention at a stage of the disease
when there is a greater chance of cure. As more data are
accumulated, it may become possible to evaluate current
screening techniques and criteria, and to improve them in
light of accumulated information, with the establishment
of more comprehensive programs for earlier and more ef-
fective screening.
Possible expanded role of targeted therapies Cur-
rently, targeted therapies for HCC are finding applications
Figure 7 A portion of a simplified entity-relationship diagram for a relational database that may be linked to a graph database for
research in biomarker and targeted therapies is shown displaying the 5th-order information entities relating to biomarkers and
targeted therapies for HCC.
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in patients with advanced disease. However, it may also be
possible to expand the role of targeted therapies in the fu-
ture to influence the development or progression of dis-
ease in earlier stages. It may even become possible to shift
high-risk patients into low-risk categories, thereby avert-
ing the development of HCC altogether.
Improved outcomes with further personalized approach
The BCLC staging system algorithm is concerned primarily
with the initial treatment choices for patients with HCC.
While several treatment options are indicated for patients
with intermediate and advanced disease, the complexities
relating to these treatment options have not yet been devel-
oped within the context of the algorithm (although these
issues are discussed elsewhere [29-31]). The ITS-PM may
be employed to generate MBME to obtain a better under-
standing of the role of locoregional treatment options and
combined treatments and the effectiveness of down-staging
Figure 8 It may be possible to build on the BCLC staging system platform with an IT system for personalized medicine (ITS-PM). The
first goal will be, through enhanced screening, to have patients seek medical attention earlier in the course of their disease, so that they may
enter the algorithm at a more favorable stage; i.e. a ‘shift to the left’. The second goal will be to improve outcomes through a better
understanding of treatment subcategories, combined treatments and the effects of down-staging.
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and/or bridging therapies to achieve improved outcomes.
The algorithm may be expanded to include, in greater de-
tail, the currently available treatments for HCC, individually
or in combination (Figure 8).
New algorithms
Patients with HCC are treated according to the best
available practices with the intention of achieving cure
and/or improved quality and length of life. Additional
algorithms are presented here that are based on current
best practices. These algorithms relate to alternative
and/or combined therapies for patients with early, inter-
mediate and advanced stages of diseases. They may be
used for palliative treatments, for down-staging and for
selecting treatment options with patients with progres-
sion of disease. Treatments for HCC included in these
algorithms include surgical resection, liver transplantation,
percutaneous ablation, transarterial chemoembolization
(TACE), local radiotherapy with yttrium-90 microspheres,
stereotactic body radiation therapy (SBRT) and systemic
targeted therapy with the oral multikinase inhibitor,
sorafenib.
Selection of the best regimen of therapy for patients
with intermediate disease is unclear at this time, due to in-
sufficient available information. However, it is felt that as
more patients are entered into the ITS-PHC, and as de-
tailed patient-specific models can be developed in suffi-
cient numbers, it will be possible to assess and validate the
treatment choices and criteria depicted in these algo-
rithms in a manner that heretofore has not been achiev-
able. Target benchmarks for the effective treatment of
hepatocellular carcinoma can be established. Comparative
studies of the costs of different treatment protocols may
be evaluated with respect to successes and failures in
treatment outcomes and with respect to overall quality of
care and the patient's quality of life.
New algorithms are presented here that address issues
and patient selection relating to alternatives in palliative
treatments and efforts to achieve down-staging. Cur-
rently available treatments for HCC included in these
algorithms are surgical resection, liver transplantation,
percutaneous ablation, TACE, radioembolization with
yttrium-90 microspheres, stereotactic body radiation
therapy (SBRT) and systemic targeted therapy with the
oral multikinase inhibitor, sorafenib. In accordance with
the BCLC staging system, the efficacy and safety of each
treatment modality depends on the stage of liver dis-
ease, performance status of the patient and severity of
underlying liver disease.
Treatment algorithms are presented here (Figures 9,
10 and 11) that represent extensions to the BCLC sta-
ging system algorithm by providing a flexible approach
to alternative therapies and by introducing the possibility
of down-staging and bridging therapy.
These algorithms present treatment pathways based
on the current literature and provide a framework for
Figure 9 A wider and more flexible assortment of alternative therapies and bridging therapies are introduced in this algorithm. This
algorithm continues in Figures 10 and 11 (alternative therapy charts: single and multiple lesions).
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the accumulation of data regarding specific treatment
protocols. The outcomes of these varied treatments can
be linked to extensive data collected for each patient (ac-
cording to the categories itemized in Figures 5, 6 and 7)
within the ITS-PM.
Conclusions
It is the goal of personalized medicine to identify the
best diagnostic tests and treatment modalities object-
ively, given the patient's actual clinical status. We have
presented an approach to advancing the care of patients
Figure 10 Alternative therapy chart: single lesions.
Figure 11 Alternative therapy chart: multiple lesions.
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with HCC, building on the well-established BCLC sta-
ging system, by proposing extensions to include en-
hanced screening and a means to evaluate more specific
treatment regimens. This approach will require the de-
velopment of a comprehensive ITS-PM that will utilize a
computing system for patient modeling and decision
support.
The ITS-PM system presented here is in its earliest
stages of development, as is the DPM, which is the basic
unit for this system. It is the goal of this project to de-
velop a system of Bayesian inference built on large data-
bases of individual patients that will provide a way of
giving greater emphasis to individual patient characteris-
tics in expanded patient screening programs and treat-
ment algorithms.
If sufficient data regarding each patient are collected,
it may be possible to generate knowledge that may be
generalized to achieving a more complete understanding
of the pathophysiology, prevention and treatment of
HCC. This may be accomplished through the use of en-
hanced IT with modeling and inference techniques, thus
creating a new methodology for evidence-based medi-
cine utilizing model theory, i.e. model-based medical
evidence.
In addition, as more information is gathered and vali-
dated through the ITS-PM, target benchmarks for the
effective treatment of hepatocellular carcinoma can be
established. Comparative studies of the costs of different
treatment protocols may be evaluated with respect to
successes and failures in treatment outcomes and with
respect to overall quality of care and the patient's quality
of life.
The tasks that lay before us in the immediate future
include the development of the databases that incorpor-
ate patient-specific IEs and the development of the
MEBN and the associated decision support. As these are
populated with data from a growing number of patient
records, DPMs will be developed. It will then become
possible to begin the study and validation of predictive,
preventive and personalized medicine through model-
guided therapy and model-based medical evidence.
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